Rick Simpson Oil (RSO) in New York: The Complete 2025 Guide by OilWell Cannabis

If you’re in New York and searching for Rick Simpson Oil — whether you’re in Buffalo dealing with chronic pain after years of lake-effect winters, a Long Island cancer patient exploring supportive care options, a veteran in Syracuse managing PTSD, or a Manhattan professional curious about legal cannabinoid medicine — you’ve found the most comprehensive, honest, and New York-specific RSO resource available. We’re OilWell Cannabis, and we’re not here to sell you snake oil. We’re here to give New Yorkers the complete truth about RSO, the actual science behind what works, and products that reflect that truth.

New York’s cannabis landscape has transformed dramatically. Adult-use cannabis is legal, medical dispensaries are expanding from Albany to the Adirondacks, and yet most New Yorkers still struggle to find truly comprehensive, multi-cannabinoid RSO products that match the therapeutic potential they’ve read about online. The “RSO” you find on a shelf in Rochester might be traditional high-THC oil, or it might be a CBD-dominant hemp extract — and rarely does it contain the seven-cannabinoid, terpene-rich profile that modern research suggests offers the most potential.

We created this guide because New York deserves better. Whether you’re buying from a Brooklyn wellness store, ordering online from upstate, or driving to a medical dispensary in Westchester, you deserve to know exactly what you’re getting, what the evidence actually says, and how to use it safely. This is everything we know, sourced from peer-reviewed research, third-party lab testing, and a decade of hands-on formulation work — published openly because that’s what New Yorkers need.

Understanding Rick Simpson Oil: The History Every New Yorker Should Know

Who Was Rick Simpson, and Why Does His Story Matter to New York?

Rick Simpson was a power engineer from Nova Scotia — not a doctor, not a scientist, not a medical professional. He was a blue-collar tradesman whose journey into cannabis advocacy began with personal suffering and a medical system that failed him. That experience resonates across New York, from patients in Buffalo’s healthcare deserts to those in the Bronx navigating overwhelmed public health systems.

In 1997, while working at a hospital in Moncton, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications he was prescribed either failed to help or made his condition worse. When he found relief through cannabis and asked his doctor to support it, the request was refused. That moment — being told “no” by a physician when conventional medicine had nothing left to offer — is a story New Yorkers across the state know intimately, whether they’re chronic pain patients in Utica, veterans with PTSD on Long Island, or cancer patients in Manhattan told there are no more options.

Simpson’s interest deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC was reported to slow tumor growth in mice. That study — originally intended to demonstrate harm — became a cornerstone of his advocacy, even though its findings were never replicated in controlled human cancer trials.

The 2003 Skin Cancer Story: The Moment That Changed Everything

The pivotal moment in Simpson’s story came in 2003 when he reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and claimed they disappeared within four days. Important context: No independent medical verification, biopsy confirmation, or clinical follow-up has ever been published in any peer-reviewed source. This is personal testimony, not medical evidence. Yet it became the origin story of Rick Simpson Oil and the catalyst for a global movement that eventually reached New York.

New Yorkers, especially those in high-skin-cancer-risk areas like Long Island’s beaches or upstate’s sun-exposed agricultural regions, may hear this story and feel hope. We honor that hope while being crystal clear: this is an anecdote, not clinical proof. It’s historically significant, but it is not a treatment protocol you should follow without medical supervision.

The Crusade: From Nova Scotia to New York

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil for free. Operating from his property in Maccan, Nova Scotia, he helped dozens of people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more. His story reached a global audience through the 2005 documentary Run From The Cure, which became foundational in cannabis communities worldwide — including New York’s early medical cannabis advocacy circles.

But Simpson’s advocacy brought him into direct conflict with law enforcement. The Royal Canadian Mounted Police raided his property in 2005 and 2009, charging him with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, continuing his advocacy from abroad. That pattern of legal conflict — of patients and providers being punished for cannabis before laws changed — mirrors New York’s own complex history with cannabis enforcement. From Rockefeller drug laws to the recent wave of expungements under New York’s Marijuana Regulation and Taxation Act, our state has lived this story. Simpson’s struggle was Nova Scotia’s; ours was New York’s.

Simpson’s 60-Gram Protocol: What New Yorkers Need to Know

Simpson’s core recommendation was a structured oral protocol: 60 grams of concentrated cannabis oil over approximately 90 days. The titration schedule started with a dose the size of half a grain of rice (10-15mg) three times daily, doubling every four days until reaching 1 gram (1,000mg) per day by week five. That dose was maintained until all 60 grams were consumed.

Administration methods were straightforward:

• Oral/sublingual: primary route for systemic absorption
• Topical: for skin cancers and lesions
• Inhalation: acknowledged for immediate symptom relief but not recommended as primary treatment

Important context for evaluating this protocol:

• No controlled trial validation. No randomized controlled trials, cohort studies, or well-documented case series exist evaluating this specific protocol for any cancer type or condition.
• Crude, unstandardized material. Traditional RSO potency was unknown and variable — 60-90% delta-9 THC by weight, but never lab-verified.
• Very high THC exposure. At peak dosing (1 gram per day of 60-90% THC oil), patients consumed 600-900mg of delta-9 THC daily — far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5-20mg per day.
• Real risks at these doses. Consuming 600-900mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the medical literature [1][13][14][15].
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as a primary treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What Traditional Rick Simpson Oil Was

Traditional RSO was nearly black, thick, tar-like oil with a strong cannabis and possible solvent-residual odor. It was effectively decarboxylated, THC-dominant (60-90% THC), with minor cannabinoids at natural ratios but no standardization. Terpene content was minimal to none — destroyed by the solvent and high-heat process. There was no lab testing, no Certificate of Analysis, and significant residual solvent risk from using naphtha or isopropyl alcohol.

This is crucial for New Yorkers to understand because the “RSO” you see in a Brooklyn dispensary or order online from Albany may bear little resemblance to what Simpson actually made. Modern products have evolved substantially — for good reason.

Simpson’s Claims vs. The Evidence: A New Yorker’s Guide to Critical Thinking

Simpson claimed RSO could cure cancer and many other diseases. He maintained that pharmaceutical companies and government agencies were actively suppressing this knowledge. While this conspiratorial framing resonated with many in the early cannabis movement, it must be evaluated against actual evidence.

What the preclinical literature shows: In vitro studies demonstrate that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition. This is scientifically interesting but has not translated into proven human cancer cures.

What the preclinical literature does NOT show: No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. The gap between in vitro/animal results and human outcomes is vast.

Institutional positions:

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research but does not endorse cannabis as a cancer treatment.
• FDA: Has not approved any cannabis plant product for cancer treatment.
• Health Canada: Never approved RSO for cancer.
• NCCIH: Identifies strongest evidence for rare epilepsies, chemo nausea, and HIV/AIDS appetite — not cancer cure.

What Simpson got right: He drew attention to cannabinoids as serious biomedical research when the world was ignoring them, helping create the conditions for today’s legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What he overstated: Cure claims exceeded the evidence. Encouraging patients to use RSO instead of proven cancer therapies carries genuine harm potential. Delayed or foregone treatment is a documented concern in alternative medicine.

Why OilWell’s Formulas Diverge from Traditional RSO

Our RSO is not traditional RSO. It’s informed by the tradition but deliberately different in ways that matter for New Yorkers:

1. Multi-cannabinoid approach. We include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity [20][29]. Traditional RSO was single-strain, THC-only.

2. Terpene preservation and addition. Traditional RSO had no terpenes. We include live terpenes at 5% with a defined seven-terpene profile (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene) because terpene bioactivity is plausible at the preclinical level [20]-[29].

3. THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. We preserve THCa at 1,500mg as a distinct ingredient, preserving the acidic precursor because THCa literature suggests non-psychoactive bioactivity that is lost when it converts to THC [12].

4. Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our sublingual formula contains only 90mg of delta-9 THC total (3mg/mL), while distributing 16,590mg across seven cannabinoids. This reflects broader cannabinoid research rather than single-compound dominance.

5. Product format innovation. Simpson had one crude format. We offer both sublingual oil and vape cartridges, acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety: A Critical Issue for New York DIY Makers

Traditional RSO used naphtha (petroleum-based) or 99% isopropyl alcohol — neither food-grade. Naphtha may contain benzene, toluene, and other carcinogens. Incomplete solvent purging is difficult to verify without lab testing.

Modern extraction uses food-grade ethanol or supercritical CO₂. Our products are formulated by blending individual cannabinoid distillates and isolates in a controlled environment — no naphtha, no isopropyl, no butane. We use organic MCT oil as carrier, with third-party lab testing for potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants. This is the safety standard New Yorkers should demand, especially if you live in areas where home extraction accidents have occurred (apartment buildings in Manhattan, dry climates upstate, fire-prone rural regions).

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated and psychoactive. Our sublingual formula contains 1,500mg of THCa — creating three distinct usage options for New Yorkers:

Option 1 — Raw, no heat: All 1,500mg stays as THCa, completely non-psychoactive. This is ideal for daytime use in New York’s fast-paced work environments — compatible with driving, operating machinery, or functioning at your Wall Street office or Brooklyn startup with zero impairment. The THCa evidence profile suggests anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12].

Option 2 — Fully activated, home decarboxylation: Heating at 260°F (125°C) for 45-60 minutes converts 1,500mg THCa to approximately 1,315mg delta-9 THC. Combined with the existing 90mg delta-9 THC, this yields ~1,405mg total delta-9 THC — comparable to traditional high-THC RSO, 100% legally, because activation occurs after purchase. You can decarboxylate the entire bottle or transfer a portion to oven-safe glass and activate only what you need.

Option 3 — Vape, auto-decarboxylation: Our vape cartridge operates at 400-450°F, instantly converting THCa to delta-9 THC with each puff. This is the fastest-onset RSO delivery method — 1-2 minutes — ideal for breakthrough pain, panic attacks, or acute nausea.

This design puts potency control entirely in your hands, aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual chemistry rather than rhetoric.

About OilWell Cannabis: Our Story, Our Mission

From McAllen to Montrose: A Journey That Shaped Our Commitment

OilWell Cannabis was founded by Colin Valencia in Houston, Texas — but our story begins in McAllen, Texas, one of the most economically challenged and dangerous border regions along the U.S.-Mexico border. The McAllen-Reynosa Borderplex taught us about suffering, resilience, and the desperate need for accessible alternatives when conventional systems fail. Many New Yorkers understand this: whether you’re in Rochester’s struggling industrial neighborhoods, the food deserts of the South Bronx, or rural communities in the Adirondacks where healthcare is hours away, the experience of being let down by institutions is universal.

Colin’s childhood involved transporting items across the border, witnessing violence, and losing friends to cartel activity and prison. By sixteen, he had to leave home for good. He chose cannabis over darker paths, learning the plant intimately while operating in the shadows. He later became a formally trained software engineer, doing custom development for Baylor College of Medicine — one of the most prestigious medical institutions in the Texas Medical Center. That combination of deep plant knowledge and medical-grade technical precision defines everything we do.

Bentley: The Dog Who Started It All

Our origin story isn’t a business plan — it’s a dog named Bentley. When Bentley fell paralyzed in his back legs and veterinarians recommended euthanasia, Colin refused to give up. Through a rescue worker’s question — “You’ve moved how many tons of weed and you’ve never heard of CBD?” — Colin discovered therapeutic cannabis.

He created a CBD golden paste formula. Bentley got up and brought his ball. From paralyzed to playing. Dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed specialized formulas for every age-related condition Bentley faced: neurodegeneration (CBG’s neuroprotective properties, THCa’s PPARγ agonism for brain cell protection), dementia (CBC’s role in neurogenesis), glaucoma (THC’s CB1 agonism for intraocular pressure), and crippling arthritis (multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene simultaneously).

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. The precision mattered — his life depended on formula accuracy, not guesswork. That decade of real-world formulation testing on a patient we loved more than anything is the foundation of our RSO formulas available to New Yorkers today.

Colin’s Personal Battle: PTSD, Benzos, and Peace Gummies

Colin knows pharmaceutical dependence personally. He struggled with PTSD and Xanax addiction. Using the cannabinoid knowledge developed keeping Bentley alive, he quit Xanax cold turkey — a notoriously difficult and dangerous feat.

Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This is not theoretical knowledge. He lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For New Yorkers trapped in the prescription cycle — whether you’re a veteran in Syracuse, a trauma survivor in Queens, or a professional in Manhattan self-medicating with benzos — this makes our approach credible in a way no corporate brand can replicate.

Community Validation: Featured by ABC13 Houston

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving America’s fourth-largest city — featured Colin and OilWell Cannabis in seven comprehensive news segments. Five different reporters sought us out across business, law, medicine, community health, and politics. No other Houston cannabis operator appears with that frequency or breadth.

What this means for New Yorkers: Mainstream media validation from a major-market ABC affiliate establishes credibility that transcends geography. When you’re evaluating cannabis products in New York — whether from a Buffalo dispensary, a Hudson Valley wellness shop, or an online retailer — this track record matters. These features cannot be purchased; they can only be earned.

OilWell Today: Licensed, Trusted, Growing

We operate from Montrose, Houston (810 Richmond Avenue, Houston, TX 77006). Since 2019, we’ve generated approximately $1M in annual revenue, maintain a near-5.0 Google rating, and hold a Texas DSHS license. All our artwork, formulations, and packaging are created in-house in Houston. We bring McAllen grit, Houston hustle, and a builder’s mindset to everything we do — but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy: Four Core Principles for New Yorkers

1. Accessibility over gatekeeping. No medical card required. Anyone age 21+ can purchase. We ship nationwide and internationally to customers who verify local legality. For New Yorkers in restrictive counties or those who don’t qualify for the state’s medical program, this is access that matters.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for daytime functionality in New York’s demanding work environments or decarboxylate it for full therapeutic strength at night. Whether you’re a Long Island commuter, an Albany state worker, or a Brooklyn bartender, you control the experience.

3. Open-source formulas. We publish our complete formulas publicly — every cannabinoid, every milligram, every percentage. If you can’t afford $129.99 for our sublingual oil, you can source ingredients and make your own. This is our direct echo of Simpson’s free-distribution ethos, adapted for the modern cannabinoid marketplace.

4. Evidence-informed, not evidence-overstating. The scientific documentation throughout this guide reflects our commitment to honest education. We don’t just cite research — we explain what it actually means for New Yorkers making real decisions about their health.

The Complete Science: What New Yorkers Need to Know About Cannabinoids

Research Method: How We Evaluate Evidence

We prioritize sources in this order:

1. Human clinical evidence
2. Systematic reviews and meta-analyses
3. NIH and institutional summaries
4. Preclinical and mechanistic literature

This weighting matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and preclinical pharmacology [1]-[29].

CBD: The Most Evidence-Developed Non-Psychoactive Cannabinoid

Strongest human evidence: CBD has the most credible human data, especially for seizure disorders (Epidiolex approval) [1][2]. This is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.

Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight studies reported statistically significant anxiolytic effects, but authors stressed that the clinical sample remains limited and more trials are needed before broad conclusions are justified [3].

Pain research: A 2024 systematic review concluded the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].

Sleep research: A 2023 insomnia review found the literature methodologically weak, with many studies relying on nonvalidated subjective measures and few objective sleep assessments [5].

Safety concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH also flags diarrhea, sleepiness, appetite changes, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations [1].

Bottom line for New Yorkers: CBD is the most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in specific indications (seizures) rather than broad wellness claims.

CBG: The Promising Minor Cannabinoid

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling — mechanistically interesting but not yet clinically established [7].

Potential research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings [7][8].

Caution: A 2021 pharmacology review notes that CBG is already being sold commercially while the evidence base remains thin, meaning claims frequently outrun the science [7].

Bottom line for New Yorkers: CBG is a serious research topic but should be described as a promising minor cannabinoid with limited clinical validation rather than a proven therapeutic.

Delta-8 THC: Not Just “Light” THC

Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: A 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent, likely due to weaker CB1 affinity [9].

Public-health literature: A 2023 scoping review found the delta-8 evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. It noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].

Manufacturing context: A 2024 chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, making product-byproduct and lab-testing questions matter [11].

Bottom line for New Yorkers: Delta-8 THC is a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many realize [9]-[11].

THCa: The Legal Innovation New Yorkers Can Actually Use

Evidence profile: Important chemically and formulation-wise, but low on direct human therapeutic evidence [12].

What it is: THCa is the acidic, non-psychoactive precursor of THC. It may represent a large share of THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can change over time during storage and processing [12].

Psychoactivity: THCa itself does not produce psychoactive effects associated with THC, but this distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Bottom line for New Yorkers: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa must account for possible conversion into THC [12].

For New York specifically: This is the legal breakthrough that makes our products accessible. Because THCa is not delta-9 THC at point of sale, our products are Farm Bill compliant and can ship to New York legally. You control the activation.

Delta-9 THC: The Most Clinically Established Psychoactive Cannabinoid

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed here, but also clearest adverse-effect burden [1][13]-[15].

Institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple sclerosis- and pain-related outcomes, while stressing that many other uses remain uncertain [1].

Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found that high-THC content or comparable THC:CBD ratio products may provide short-term pain benefit but increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics: Classic literature remains relevant: inhaled THC produces effects within seconds to minutes, peaks in 15-30 minutes, and tapers over hours; oral THC has later onset, later peak, and longer duration — crucial for both benefit and overconsumption risk [14].

Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader safety: Institutional literature describes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns [1][14][15].

Bottom line for New Yorkers: Delta-9 THC has legitimate therapeutic relevance in some settings but carries the clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15].

CBN: Separating Sleep Claims from Evidence

Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data [12][16][17].

What it’s marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than the market suggests [16][17].

Best direct review: A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].

Broader sleep literature: A 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still doesn’t match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial [17].

Chemical context: Review literature on THCa notes that THC can degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].

Bottom line for New Yorkers: CBN is one of the clearest examples where cultural reputation is stronger than current clinical evidence [16][17].

CBC: The Emerging Neuroprotective Cannabinoid

Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].

Pharmacology and therapeutic interest: A 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].

Older literature: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these are not yet strong evidence for patient-facing claims [19].

Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line for New Yorkers: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not already-validated clinical actives [18][19].

Terpenes: Aromatic Medicine or Marketing Hype?

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene: Citrus Brightness from Brooklyn to Buffalo

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, and immune-modulatory possibilities — but the overwhelming share of claims comes from nonhuman or non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22].

Bottom line for New Yorkers: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene: Relaxation or Placebo?

Evidence profile: Mostly preclinical, with very limited human evidence [20][23].

Research summary: A 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking [23].

Interpretation caution: Claims that myrcene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][23].

Bottom line for New Yorkers: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene: The CB2 Agonist That Matters

Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist — unusual and especially relevant when discussing cannabis terpenes in pharmacologic terms [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions are repeatedly discussed, but human clinical confirmation remains limited [24].

Bottom line for New Yorkers: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven [24].

Pinene & Linalool: Forest Fresh and Floral Calm

Pinene evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: A 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized that evidence is mostly preclinical and well-designed clinical trials are lacking [25].

Linalool evidence profile: Similar to pinene — substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing lack of robust human trials [25]. Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance [26].

Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line for New Yorkers: Both are scientifically credible as bioactive terpenes, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene & Terpinolene: Earthy Depth and Complex Aroma

Humulene evidence profile: Translationally interesting but still early [20][27].

Scoping-review findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Findings are valuable for hypothesis generation but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Terpinolene evidence profile: One of the least clinically characterized terpenes in this file [20][28].

Systematic-review findings: A 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].

Bottom line for New Yorkers: Both are biologically interesting, but among listed terpenes they remain especially underdeveloped clinically [27][28].

Product Details: What New Yorkers Are Actually Buying

RSO Sublingual Oil — $129.99

Specifications:

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg per mL)
• Seven cannabinoids:
  • CBD: 4,500mg
  • CBG: 3,000mg
  • Delta-8 THC: 6,000mg
  • THCa: 1,500mg
  • Delta-9 THC: 90mg
  • CBN: 750mg
  • CBC: 750mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1mL dosing
• Onset: 15-45 minutes
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximately 40-60 doses per bottle

RSO Vape Cartridge — $49.99

Specifications:

• 1-gram cartridge
• 900mg+ total cannabinoids
• Six cannabinoids:
  • CBD: 30%
  • CBG: 20%
  • Delta-8 THC: 15%
  • THCa: 10%
  • CBN: 10%
  • CBC: 10%
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format in New York

Use Case	Recommended Format	Why It Works for New Yorkers
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset — perfect for NYC subway panic attacks or sudden breakthrough pain in a Buffalo winter
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration — covers your workday in Albany or evening in Rochester
Maximum bioavailability	Sublingual	13-19% absorption — gets more medicine into your system
Portability/discretion	Vape	Compact, no measuring — discrete for use in public spaces or at work
Precise dosing control	Sublingual	Graduated dropper in 0.1mL increments — essential for titration
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive — zero impairment for Long Island commutes or upstate farm work
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC for full therapeutic strength while you sleep

Competitive Comparison: How OilWell RSO Stacks Up in New York

OilWell RSO vs. New York Medical Dispensary RSO

Dimension	NY Medical Dispensary RSO	OilWell RSO
Cannabinoid profile	Typically THC-only or THC:CBD simple ratios	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	Usually 0mg	3,000mg
CBN content	Usually 0-50mg	750mg
CBC content	Usually 0mg	750mg
Patient-controlled potency	No — always psychoactive	Yes — THCa non-psychoactive until you heat it
Access requirements	NY medical card + qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, HIV/AIDS, ALS, Parkinson’s, MS, epilepsy, etc.	None required
Delivery	Must travel to physical dispensary (limited locations outside NYC)	Ships directly to your New York address, same-day in Houston zone for NY visitors
Farm Bill compliance	No — state medical program	Yes — <0.3% delta-9 THC at sale

For New Yorkers in rural areas like the Adirondacks or Western New York, where medical dispensaries are hours away, direct shipping is game-changing.

OilWell RSO vs. NY Hemp CBD RSO Products

Dimension	Typical NY Hemp RSO (10mL, 1,000mg)	OilWell RSO (30mL, 16,590mg)
Total cannabinoids	1,000mg	16,590mg
CBD content	~950mg	4,500mg
CBG content	0-20mg	3,000mg
Delta-8 THC	0mg	6,000mg
THCa (convertible)	Minimal	1,500mg (~1,315mg delta-9 THC when activated)
Psychoactive option	No meaningful effect	Yes — via THCa decarboxylation and delta-8 THC
Price	$40-50	$129.99

Cost per mg of cannabinoids: OilWell provides far more therapeutic potential per dollar, critical for New Yorkers facing the state’s high cost of living.

Why Our Open-Source Formula Matters in New York

We publish our complete formulas — every milligram, every percentage — publicly. For price-sensitive New Yorkers in economically challenged areas (South Bronx, parts of Buffalo, rural counties), this is revolutionary. If you can’t afford $129.99, you can source cannabinoid distillates and make your own version using our exact recipe.

This is our direct echo of Rick Simpson’s original ethos: he gave oil away for free and taught people to make it. We sell a professionally manufactured, lab-tested, standardized product for those who want it, and publish the recipe for those who want to make it themselves.

Colin’s foundational quote from our first ABC13 feature in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

That principle guides everything we do for New Yorkers.

Delivery and Access: Getting OilWell RSO to New York

Nationwide Shipping to Every New York County

We ship to all 50 states where Farm Bill-compliant products are legal — which includes New York. Whether you’re in:

• NYC’s five boroughs (Manhattan, Brooklyn, Queens, The Bronx, Staten Island)
• Long Island (Nassau and Suffolk Counties)
• The Hudson Valley (Westchester, Rockland, Putnam, Dutchess, Orange, Ulster, Sullivan)
• Capital Region (Albany, Rensselaer, Saratoga, Schenectady)
• Western New York (Buffalo, Rochester, Syracuse, Erie County, Monroe County, Onondaga County)
• The North Country (Adirondacks, Plattsburgh, Watertown)
• Southern Tier (Binghamton, Elmira, Corning)
• Central New York (Utica, Rome, Oneida County)
• The Finger Lakes (Ithaca, Geneva, Auburn)
• The Southern Tier (Jamestown, Olean)

Your order ships via:

• USPS Priority Mail (2-3 business days)
• FedEx/UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Temperature-stable packaging for summer heat waves
• Tracking provided for all orders
• Signature-required option available

New York-Specific Legal Framework

New York legalized adult-use cannabis in 2021. However, the state’s legal market is still developing, and many New Yorkers live in “cannabis deserts” where licensed dispensaries are hours away. Our products fill that gap legally.

Farm Bill Compliance: Our sublingual oil contains only 90mg delta-9 THC in the entire 30mL bottle (3mg/mL), well under the 0.3% threshold. All cannabinoids are hemp-derived. This makes it legal under both federal law and New York law at the point of sale.

THCa Conversion: The 1,500mg THCa in each bottle can be converted to approximately 1,315mg delta-9 THC by heating at 260°F for 45-60 minutes. Combined with the existing 90mg delta-9, this yields ~1,405mg total delta-9 THC — comparable to traditional illegal RSO, entirely at your legal discretion after purchase.

Customer responsibility: You are responsible for understanding and complying with local New York laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. Possession limits in New York (3 ounces of cannabis, 24 grams of concentrate for adult-use) apply to activated products, not raw THCa oil.

For New York Visitors to Houston

If you’re a New Yorker visiting Houston for medical treatment at the Texas Medical Center (the world’s largest medical complex, treating many New York patients seeking specialized care), we offer free same-day delivery to all 60+ TMC institutions — MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more. Whether you’re from Manhattan seeking oncology treatment or from Albany for a transplant, we can deliver directly to your hospital or lodging.

Condition-Specific Usage Context for New Yorkers

IMPORTANT DISCLAIMER: The following contexts are informed by cannabinoid research cited throughout this document and by our formulation rationale. They are NOT medical prescriptions, NOT FDA-approved treatment protocols, and NOT substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment — provides antiemetic cannabinoid coverage using delta-8 THC’s established anti-nausea profile [9].

Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset) — critical when nausea hits suddenly during treatment at Memorial Sloan Kettering or Roswell Park.

Post-chemo: 0.5mL sublingual every 6 hours as needed — sustained relief without constant redosing.

Sleep support during treatment: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN) — addresses treatment-related insomnia without additional pharmaceuticals.

Evidence context: Delta-8 antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3].

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

Common in New York: Whether it’s the fibromyalgia epidemic affecting women across the state, arthritis from upstate’s harsh winters, or neuropathy from Long Island’s diabetes prevalence, chronic pain is a New York crisis.

Daytime: 0.3-0.5mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment. Essential for functioning at work, driving through NYC traffic, or operating equipment on a Western New York farm.

Nighttime: 0.5-1.0mL decarboxylated sublingual — combines pain relief with CBN sleep support.

Breakthrough pain: Vape as needed for rapid onset.

Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12].

Sleep Support for Insomniac New Yorkers

Before bed: 1.0-2.0mL sublingual.

• At 2.0mL, delivers 50mg CBN — the dosage level investigated in 2024 sleep literature.
• At 1.0mL, delivers 25mg CBN — above the 20mg threshold associated with reduced sleep disturbance in published research.

For New York’s shift workers (healthcare workers in Manhattan, factory workers in Syracuse, truckers crossing the Thruway), this addresses disrupted circadian rhythms without the hangover of traditional sleep medications.

Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature.

Anxiety and Stress in High-Pressure New York Environments

Daytime functional relief: 0.3mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment. Perfect for Wall Street traders, Albany lobbyists, or NYC teachers managing classroom stress.

Nighttime: 1.0mL sublingual — full cannabinoid profile including CBN for sleep architecture.

Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20].

General Titration Principle for New Yorkers: Start Low, Go Slow

Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on:

• Body weight
• Metabolism
• Tolerance
• Concurrent medications (especially important for New Yorkers on multiple prescriptions)
• Liver function (relevant given CBD’s potential liver enzyme effects [6])

New York-specific considerations:

• Polypharmacy is common among older New Yorkers and those with complex conditions. Start lower and monitor drug interactions.
• Liver disease prevalence in certain NYC communities (hepatitis, fatty liver) makes liver enzyme monitoring essential.
• Workplace drug testing is still common in New York financial, government, and healthcare sectors. Raw THCa will not cause positive tests; decarboxylated or vape forms will.

Common Overstatements New Yorkers Should Avoid

1. “CBN is a clinically proven sleep aid.”
   More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].

2. “Myrcene makes you sleepy.”
   More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for sedation claims is limited [20][23].

3. “Terpenes have proven entourage effects.”
   More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

4. “THCa is always non-psychoactive.”
   More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].

5. “Delta-8 THC is safe because it’s hemp-derived.”
   More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for New Yorkers

1. CBD and delta-9 THC have the most evidence-developed profiles in our formulas.
2. Delta-8 THC is not a trivial or purely mild ingredient; it’s a psychoactive cannabinoid with less robust safety characterization than delta-9 THC.
3. THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
4. CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC.
5. Terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully.

Legal Compliance and Safety for New York

Age requirement: 21+ for all RSO products.

THC content compliance: All products contain less than 0.3% delta-9 THC; Farm Bill compliant; hemp-derived cannabinoids.

FDA disclaimers: Not evaluated by FDA; not intended to diagnose, treat, cure, or prevent any disease; consult healthcare provider before use; individual results may vary.

Safety warnings: May cause drowsiness or impairment; do not operate vehicles or machinery; consult physician if pregnant or nursing; keep out of reach of children.

Legal responsibility: Buyer responsibility to check local New York laws; company assumes no legal responsibility for customer’s use or decarboxylation decisions; void where prohibited by law.

New York-specific considerations:

• Driving: New York has strict impaired driving laws. Do not drive after consuming activated/decarboxylated products.
• Workplace: Many New York employers still drug test. Raw THCa products will not cause positive tests; activated products will.
• Public consumption: New York legalized public consumption in many areas, but private property rules vary. Use discretion.
• Storage: Keep raw THCa products cool to prevent accidental decarboxylation during hot New York summers.

Contact and Ordering for New Yorkers

Website: oilwellcbd.com

Phone: (832) 416-2816

Email: [email protected]

Instagram: @oilwellcbd

Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

For New York orders: We ship Monday-Saturday. Orders placed before 2 PM Central Time ship same business day. You’ll receive tracking via email. Typical delivery to NYC, Long Island, and downstate areas is 2-3 business days via USPS Priority. Upstate New York deliveries typically arrive in 3-5 business days.

For same-day Houston delivery: If you’re a New Yorker visiting Houston for medical treatment, call us. We deliver free to the Texas Medical Center and can often get product to your hospital room or hotel within hours.

Why New Yorkers Choose OilWell RSO

Because we tell the truth when others won’t — about Simpson, about the evidence, about risks, about limitations.

Because our formula is transparent when others hide behind proprietary blends — we publish every milligram.

Because we give you control when others decide for you — raw THCa or activated THC, your choice.

Because we ship to New York when others can’t or won’t — legally, discreetly, reliably.

Because our story is real — from Bentley’s miracle to Colin’s conviction to our ABC13 validation — not manufactured marketing.

Because we understand New York — from the five boroughs to the North Country, from Wall Street stress to upstate farm pain, from veteran PTSD in Syracuse to cancer patients in Manhattan.

Because you deserve the best possible version of cannabinoid medicine to give it a fair shot and decide if it’s right for you.

This is OilWell RSO. This is what New Yorkers have been searching for.

Complete Product Index for New York Shoppers

RSO Sublingual Oil — Buy Now — $129.99

RSO Vape Cartridge — Buy Now — $49.99

Asshole Peach Gummy Rings — $39.99 — Our best-selling product, favored by veterans for PTSD and pain relief — 268mg total cannabinoids per ring: 28mg Delta-9, 50mg Delta-8, 20mg Delta-10, 20mg THCo, 100mg CBD, 50mg CBG

Peace Gummy Peaches — $34.99 — Sleep & recovery formula born from Colin’s personal benzo withdrawal — 320mg total cannabinoids per peach: 30mg CBN, 15mg Delta-9, 25mg Delta-8, 100mg CBD, 150mg CBG

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy — $39.99 — 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate — zero sugar, 100% vegan

Custom Creations — Contact us for tailored formulations for specific cannabinoid ratios, delivery formats, or health circumstances including vegan, diabetic, and specific dietary needs.

The Bottom Line for New Yorkers

New York’s cannabis revolution is here — but access, quality, and honesty remain inconsistent. Whether you’re in Manhattan’s Financial District, a farm in the Finger Lakes, a manufacturing town in the Southern Tier, or a coastal community on Long Island, you deserve the same standard of cannabinoid medicine: transparent, evidence-informed, legally accessible, and effective.

Our open-source formulas honor Rick Simpson’s original vision of accessible medicine. Our multi-cannabinoid approach reflects the latest science. Our patient-controlled potency respects your autonomy. Our shipping model serves every corner of New York state.

This is more than a product. It’s a promise to New Yorkers that cannabis medicine can be done right — with integrity, precision, and heart.

Order today at oilwellcbd.com or call (832) 416-2816 to speak with our team about your specific New York needs.